TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers
暂无分享,去创建一个
Jorge S Reis-Filho | J. Reis-Filho | B. Weigelt | C. Ng | R. Soslow | L. Martelotto | M. D. De Filippo | A. Schultheis | Britta Weigelt | Robert A Soslow | Charlotte K Y Ng | Anne M Schultheis | Luciano G Martelotto | Maria R De Filippo | Salvatore Piscuglio | Yaser R Hussein | Yaser R. Hussein | S. Piscuglio
[1] J. V. Bokhman. Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.
[2] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[3] Kathleen R. Cho,et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. , 1997, The American journal of pathology.
[4] R. Slebos,et al. The frequency of p53, k‐ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma , 2000, Cancer.
[5] P. Hall,et al. Assessing p53 in clinical contexts: unlearned lessons and new perspectives , 2006, The Journal of pathology.
[6] R. Broaddus,et al. Pathologic features of endometrial carcinoma associated with HNPCC , 2006, Cancer.
[7] M. Olivier,et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.
[8] A. Fersht,et al. Structure–function–rescue: the diverse nature of common p53 cancer mutants , 2007, Oncogene.
[9] Il-Jin Kim,et al. FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression , 2008, Science.
[10] Varda Rotter,et al. When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.
[11] K. Kosarin,et al. Selection of Endometrial Carcinomas for DNA Mismatch Repair Protein Immunohistochemistry Using Patient Age and Tumor Morphology Enhances Detection of Mismatch Repair Abnormalities , 2009, The American journal of surgical pathology.
[12] M. Köbel,et al. High-Grade Endometrial Carcinoma: Serous and Grade 3 Endometrioid Carcinomas Have Different Immunophenotypes and Outcomes , 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[13] Jeong-Won Lee,et al. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review. , 2010, Gynecologic oncology.
[14] P. Radice,et al. Lynch Syndrome—Related Endometrial Carcinomas Show a High Frequency of Nonendometrioid Types and of High FIGO Grade Endometrioid Types , 2010, International journal of surgical pathology.
[15] R. Soslow. Endometrial carcinomas with ambiguous features. , 2010, Seminars in diagnostic pathology.
[16] Magali Olivier,et al. TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.
[17] G. Sica,et al. p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes , 2010, Modern Pathology.
[18] H. Aburatani,et al. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] E. Oliva,et al. Endometrial Carcinomas: A Review Emphasizing Overlapping and Distinctive Morphological and Immunohistochemical Features , 2011, Advances in anatomic pathology.
[20] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[21] C Blake Gilks,et al. Patterns of p53 immunoreactivity in endometrial carcinomas: ‘all or nothing’ staining is of importance , 2011, Histopathology.
[22] G. Mills,et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. , 2011, Cancer discovery.
[23] Varda Rotter,et al. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. , 2011, Genes & cancer.
[24] Thomas Zeng,et al. Use of mutation profiles to refine the classification of endometrial carcinomas , 2012, The Journal of pathology.
[25] R. Coleman,et al. The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer , 2012, Clinical Cancer Research.
[26] Carol Prives,et al. Mutant p53: one name, many proteins. , 2012, Genes & development.
[27] Tian-Li Wang,et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. , 2012, Journal of the National Cancer Institute.
[28] Dennis C. Sgroi,et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes , 2016 .
[29] A. Matamoros,et al. Tumors of the uterine corpus , 2012 .
[30] G. Mills,et al. Clinical Assessment of PTEN Loss in Endometrial Carcinoma: Immunohistochemistry Out-Performs Gene Sequencing , 2011, Modern Pathology.
[31] B. Weigelt,et al. Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer , 2012, Front. Oncol..
[32] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[33] K. Vousden,et al. p53 mutations in cancer , 2013, Nature Cell Biology.
[34] U. McDermott,et al. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. , 2013, Cancer discovery.
[35] Julian Downward,et al. PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines , 2013, Clinical Cancer Research.
[36] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[37] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[38] A. Myers. New Strategies in Endometrial Cancer: Targeting the PI3K/mTOR Pathway—The Devil Is in the Details , 2013, Clinical Cancer Research.
[39] X. Matías-Guiu,et al. Molecular pathology of endometrial carcinoma , 2013, Histopathology.
[40] S. Leung,et al. Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas , 2013, The American journal of surgical pathology.
[41] R. Soslow. High‐grade endometrial carcinomas – strategies for typing , 2013, Histopathology.
[42] A. Spurdle,et al. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. , 2013, Gynecologic oncology.
[43] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[44] Carlos Caldas,et al. TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance , 2014, Clinical Cancer Research.
[45] R. Soslow,et al. Updates in diagnostic immunohistochemistry in endometrial carcinoma. , 2014, Seminars in diagnostic pathology.
[46] R. Melamed,et al. FBXW7 mutations in melanoma and a new therapeutic paradigm. , 2014, Journal of the National Cancer Institute.
[47] J. Reis-Filho,et al. Epistatic interactions and drug response , 2014, The Journal of pathology.
[48] Karen H. Vousden,et al. Mutant p53 in Cancer: New Functions and Therapeutic Opportunities , 2014, Cancer cell.
[49] Zhiwei Wang,et al. Aberrant regulation of FBW7 in cancer , 2014, Oncotarget.
[50] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[51] B. Weigelt,et al. Classification of endometrial carcinoma: more than two types. , 2014, The Lancet. Oncology.
[52] M. Socinski,et al. Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation. , 2014, Lung cancer.
[53] B. Clarke,et al. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas , 2014, Modern Pathology.
[54] Pieter Wesseling,et al. International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading , 2014, Brain pathology.
[55] P. Taschner,et al. Recommendations for Analyzing and Reporting TP53 Gene Variants in the High‐Throughput Sequencing Era , 2014, Human mutation.
[56] T. Soussi,et al. TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade , 2014, Human mutation.
[57] M. Köbel,et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. , 2014, Gynecologic oncology.
[58] B. Karlan,et al. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations , 2015, Modern Pathology.
[59] P. Pollock,et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative , 2015, Modern Pathology.
[60] D. Lambrechts,et al. Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer , 2014, Journal of the National Cancer Institute.
[61] D. Levine,et al. The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and Reproducibility , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.